



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

JFw

APPLICANTS: Thomas Kelly, et al.

GROUP ART UNIT: 3736 Confirmation No. 8102

SERIAL NO.: 10/738,446

EXAMINER: Unknown

FILING DATE: December 16, 2003

ATTY. DOCKET NO.: DI-5928 (112713-457)

For: MEDICAL FLUID THERAPY FLOW CONTROL SYSTEMS AND METHODS

Mail Stop: Amendment
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Dear Sir/Madam:

Submitted herewith is an Information Disclosure Statement for consideration in the above-identified application. This Information Disclosure Statement is submitted:

Within 3 months (1) of filing date of a national application; (2) of date of entry of the national stage as set forth in 37 CFR §1.491 in an international application; or (3) before the mailing date of a first Office Action on the merits, whichever occurs last. (No fee is required.)

After the mailing date of a first Office Action but before (1) mailing of a final action under 37 CFR §1.311, whichever occurs first.

Please charge payment for the fee set forth in 37 CFR §1.17(i)(1) to Deposit Account No. 02-1440.

The certification specified in 37 CFR §1.97(e) is made below. (No fee is required.)

After the mailing of (1) a final action under 37 CFR §1.113; or (2) a notice of allowance under 37 CFR §1.311 whichever occurs first, but before payment of the issue fee. The certification specified in 37 CFR §1.97(e) is made below. The Commissioner hereby is petitioned to consider the Information Disclosure Statement accompanying the submission.

The undersigned counsel for applicant(s) hereby certifies that the item of information identified in the Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement while all others were already cited in previous Information Disclosure Statements and accompanying documents.

The undersigned counsel for applicant(s) hereby certifies that some items of information contained in the Information Disclosure Statement were not cited in a communication from a foreign Patent Office in a counterpart foreign application, or to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of the statement.

The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment to Account No. 02-1440. *A duplicate copy of this sheet is enclosed for this purpose.*

Very respectfully,

Baxter Healthcare Corporation

 Reg. No. 35,332

Joseph P. Reagan
Baxter International Inc.
One Baxter Parkway
Deerfield, Illinois 60015
Telephone: (847) 948-3315


When phoning re this application,
please call (847) 948-2000

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 8, 2005.

 Reg. No. 35,332

90664V3

Joseph P. Reagan



NOV. 14 2005

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheets

1

of

1

Complete if Known

Application Number	10/738,446
Filing Date	December 16, 2003
First Named Inventor	T. Kelly, et al.
Art Unit	3736
Examiner Name	Unknown
Attorney Docket Number	DI-5928 (112713-457)

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	A2	WO 2001/32238 A2	05-10-2001	INFOMED S.A.		
	A3	DE 10210179 C1	08-07-2003	FRESENIUS MEDICAL		
	A4	EP 1175917 A1	01-30-2002	FRESENIUS MEDICAL		
	A5	WO 2004/069311 A1	08-19-2004	GAMBRO LUNDIA AB		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.